In a reminder that stretched valuations make for poor timing signals, Piper Sandler strategist Michael Kantrowitz observed in ...

Microsoft's upcoming earnings report could be mixed due to new metrics published in August that are not yet fully reflected ...

In a report released today, Matthew Clark from Piper Sandler maintained a Hold rating on Washington Federal (WAFD – Research Report), ...

In a report released today, David Amsellem from Piper Sandler reiterated a Hold rating on Supernus Pharmaceuticals (SUPN – Research ...

We recently compiled a list of the 20 Trending AI Stocks on Latest News and Ratings. In this article, we are going to take a ...

Piper Sandler believes Microsoft (NASDAQ: MSFT)'s upcoming earnings report on October 30 could be "mixed," citing challenges ...

According to investment firms Piper Sandler and Gavekal Research, recent polling shifts suggest that markets may be preparing ...

Fintel reports that on October 14, 2024, Piper Sandler upgraded their outlook for SentinelOne (NYSE:S) from Neutral to ...

Fintel reports that on October 16, 2024, Piper Sandler initiated coverage of Walt Disney (NYSE:DIS) with a Neutral ...

US stocks gained on Monday with the S&P 500 (^GSPC) and Dow Jones Industrial Average (^DJI) reaching fresh record highs. Josh ...

MINNEAPOLIS--(BUSINESS WIRE)--Piper Sandler Companies (NYSE: PIPR), a leading investment bank, will release its third quarter 2024 financial results prior to the opening of the market on Friday ...

On Friday, Akebia Therapeutics Inc (AKBA) stock saw a modest uptick, ending the day at $1.34 which represents a slight increase of $0.01 or 0.75% from the prior close of $1.33. The stock opened at $1.